Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical trial. This study evaluated Camzyos (mavacamten), which is a cardiac myosin inhibitor/CMI, in adolescent patients aged 12 to under 18 years suffering from symptomatic obstructive hypertrophic cardiomyopathy/oHCM. This rare genetic disease causes heart muscle thickening that obstructs blood flow, leading to significant fatigue and restricted physical activity in young patients.

The SCOUT-HCM trial successfully met its primary endpoint by demonstrating a statistically significant reduction in the Valsalva left ventricular outflow tract/LVOT gradient at Week 28 compared to a placebo. This measurement indicates that the medication effectively reduced the physical obstruction in the heart. Furthermore, the trial reached statistical significance across multiple secondary endpoints. These results suggest that Camzyos could become the first CMI specifically approved for the adolescent population, who currently rely on limited medical management or invasive surgeries.

Camzyos functions as a selective, reversible, allosteric inhibitor of cardiac myosin. It targets the underlying pathophysiology of HCM by inhibiting the formation of excess myosin-actin cross-bridges in the sarcomere, which reduces the heart’s hypercontractility. By easing the dynamic LVOT obstruction and improving cardiac filling pressures, the therapy helps patients become more active in their daily lives. Currently, 4,000+ healthcare providers in the US use this treatment for adults with symptomatic NYHA class II-III oHCM. However, Bristol-Myers Squibb Company’s (NYSE:BMY) Camzyos also carries a Boxed Warning regarding the risk of heart failure.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.